Could a transplant drug shrink Children's birthmarks?
NCT ID NCT02509468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug sirolimus (rapamycin) in 63 children aged 6 to 18 with large, complicated slow-flow vascular malformations (abnormal blood or lymph vessels). Each child had an observation period followed by 4 to 8 months of sirolimus treatment. The main goal was to see if the malformation shrank on MRI scans. The trial is completed, and results may help decide if sirolimus is a useful treatment for these rare conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (also known as rapamycin)
What this could lead to
If it works, this could point toward a drug treatment to shrink or control problematic vascular malformations in children, reducing pain and complications.
What could go wrong
This is a small, early-phase trial with only 63 children and no placebo group. The results may not apply to all types of malformations, and sirolimus can have side effects like mouth sores and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Consultations externes de Dermatologie, Hôpital Clocheville, CHU Tours
Tours, 37000, France
-
Explorations Médecine Vasculaire Hôpital A. Michallon, CHU de Grenoble
Grenoble, 38700, France
-
Service de Dermatologie, Hôpital Hôtel-Dieu, CHU Nantes
Nantes, 44000, France
-
Service de Dermatologie, Hôpital Pontchaillou, CHU RENNES
Rennes, 35000, France
-
Service de Dermatologie, Hôpital St Eloi, CHU Montpellier
Montpellier, 34000, France
-
Service de Dermatologie, vénéréologie et cancérologie cutanée, Hôpital La Timone APHM
Marseille, 13000, France
-
Service de dermatologie, APHP Necker
Paris, 75743, France
-
Service de dermatologie, CHU Angers
Angers, 49933, France
-
Service de dermatologie, CHU Nice
Nice, 06202, France
-
Service de dermatologie, Hôpital Larrey, CHU Toulouse
Toulouse, 31059, France
-
Service de dermatologie, Hôpital du Bocage, CHU Dijon
Dijon, 21079, France
-
Service de radiologie Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon
Lyon, 69000, France